Objective
Our goal is to develop an improved injectable material that could help treat Type 1 diabetes by delivering and protecting insulin-producing cells in the body. People with Type 1 diabetes currently need constant blood sugar monitoring and multiple daily insulin injections because their bodies cannot produce insulin naturally. While transplanting insulin-producing cells could potentially cure the disease, these cells often don't survive long enough in the body to provide lasting benefits.
We've created a special material called MAP that can be injected under the skin and has already proven safe in human trials for wound healing. This material is unique because it has tiny spaces throughout its structure that allow it to work well with the body's tissues without causing scarring. In this study, we aim to make two key improvements to MAP to help it better support transplanted insulin-producing cells:
Make the material last longer in the body so it can protect the transplanted cells for an extended period
Help more blood vessels grow into the material so the transplanted cells get better access to oxygen and nutrients
If successful, this improved material could lead to a one-time injection treatment that helps restore natural insulin production in people with Type 1 diabetes, potentially freeing them from the burden of daily insulin injections and constant blood sugar monitoring. Because we're building on a material that's already being tested in humans, our approach offers a clearer path to potential clinical use compared to completely new technologies.
Background Rationale
Type 1 diabetes affects more than 1.4 million Americans, requiring them to monitor their blood sugar levels and inject insulin multiple times daily throughout their lives. While replacing lost insulin-producing cells through transplantation could potentially cure the disease, current approaches face two major obstacles: the transplanted cells often don't get enough blood supply to survive, and the body's immune system tends to attack and reject them.
Recent clinical studies have highlighted these challenges. For example, a 2023 study found that when insulin-producing cells were transplanted using current methods, they stopped working within a year because scar tissue formed around them, cutting off their blood supply. This shows why we need a better way to deliver and protect these cells.
Our team has developed a promising solution called MAP (Microporous Annealed Particle) scaffolds. Think of MAP as a protective framework with tiny interconnected spaces throughout - similar to the structure of a sponge. This unique design allows it to integrate with the body's tissues without triggering the scarring response that typically occurs around medical implants. We've already shown that MAP works well in various applications, from helping heal wounds to repairing damaged heart tissue, and it's currently being tested in human clinical trials for wound healing.
Our preliminary research shows that when we use MAP to deliver insulin-producing cells, they can function for about three months before the material begins to break down. This is promising, but not long enough for a lasting treatment. We've also discovered that we can enhance blood vessel growth within MAP by incorporating natural growth factors that the body already uses to build blood vessels.
This project builds on these findings by making MAP more durable and better at supporting blood vessel growth, while keeping all the beneficial properties that make it work so well with the body's tissues. Because we're improving an existing technology that's already proven safe rather than creating something entirely new, our approach offers a faster path to potentially helping patients.
Description of Project
Type 1 diabetes affects over 1.4 million Americans who must rely on constant blood sugar monitoring and insulin injections throughout their lives. While transplanting insulin-producing cells (called islets) could potentially cure the disease, current approaches face major challenges. The transplanted cells often fail to survive long-term because they don't get enough blood supply and face rejection from the patient's immune system.
Our research team has developed a promising technology called MAP (Microporous Annealed Particle) scaffolds that could overcome these challenges. MAP scaffolds are injectable materials with a unique structure that allows them to integrate well with the body's tissues while avoiding the scarring response that typically occurs around implanted materials. This technology is already being tested in human clinical trials for wound healing, showing its strong potential for medical use.
In this project, we aim to adapt our MAP technology specifically for delivering insulin-producing cells to treat type 1 diabetes. Our approach builds on MAP's proven safety while making two key improvements: enhancing how long the scaffold stays stable in the body and improving blood vessel growth around the transplanted cells.
The first improvement involves modifying the chemical structure of MAP to make it more resistant to breaking down in the body. Our initial studies show that standard MAP maintains transplanted cell function for about three months before declining. By making MAP more durable, we expect to significantly extend this timeframe, potentially providing long-term diabetes treatment from a single injection.
The second improvement focuses on helping blood vessels grow into the scaffold more quickly and extensively. We'll do this by incorporating a controlled release system for VEGF, a natural protein that stimulates blood vessel formation. This should help the transplanted cells get better access to oxygen and nutrients, improving their survival and function.
What makes our approach particularly promising is that it builds on technology that's already shown to be safe in humans. Many other approaches require developing entirely new materials, which faces a long path to clinical testing. In contrast, we're enhancing an existing platform that's already proven to integrate well with the body's tissues.
Our research will progress through three main stages:
Developing and testing more durable versions of MAP
Optimizing the blood vessel growth system
Combining these improvements and testing them in relevant diabetes models
If successful, this research could lead to a minimally invasive treatment option for type 1 diabetes. Instead of requiring multiple daily insulin injections and constant blood sugar monitoring, patients might receive a single injection of insulin-producing cells supported by our enhanced MAP scaffold. This could potentially restore natural insulin production and blood sugar control.
The project also establishes a clear path toward clinical testing. Since MAP is already in human trials for wound healing, we have a roadmap for testing and approval. Additionally, our approach focuses on making the transplanted cells survive longer rather than trying to prevent immune rejection, which means it could be combined with existing anti-rejection medications already used in transplant procedures.
Looking ahead, success in this project would lead to testing in larger animal models and eventually human clinical trials. We're also exploring ways to combine this technology with other approaches being developed in our lab to further improve transplant success. The ultimate goal is to develop a practical, long-lasting treatment option that could significantly improve the lives of people living with type 1 diabetes.
Anticipated Outcome
If successful, this research will produce an improved injectable material that could offer a long-lasting treatment option for people with Type 1 diabetes. We expect our enhanced version of MAP to protect and support transplanted insulin-producing cells for at least six months to a year, significantly longer than the three months we can currently achieve.
The immediate benefits we anticipate include:
-A material that lasts longer in the body while maintaining its protective properties
-Better blood vessel growth around the transplanted cells, helping them survive and function
-The ability to achieve blood sugar control with fewer transplanted cells, making the treatment more efficient
-A single injection approach that could replace the need for multiple daily insulin injections
Looking ahead, successful results from this study would lead to:
-Testing in larger animal models to further confirm safety and effectiveness
-Development of standardized manufacturing processes to ensure consistent production
-Discussions with the FDA about the path to human clinical trials
-Planning for initial safety studies in humans
The long-term impact could be transformative for diabetes treatment. Instead of requiring constant blood sugar monitoring and multiple daily insulin injections, patients might receive a single injection of insulin-producing cells in our enhanced MAP material. This could restore their body's natural ability to control blood sugar levels, dramatically improving their quality of life.
Importantly, because we're building on a material that's already being tested in human clinical trials, we have a clearer and potentially faster path to bringing this technology to patients. Our approach is also designed to work alongside existing anti-rejection medications, making it easier to integrate into current medical practices.
Relevance to T1D
Type 1 diabetes is a lifelong condition that affects over 1.4 million Americans, requiring them to carefully monitor their blood sugar levels and take insulin injections multiple times every day. While these treatments help manage the disease, they place a significant burden on patients and don't address the underlying cause - the loss of insulin-producing cells in the body.
Our research directly addresses this fundamental problem by developing a better way to replace these lost cells. Current cell replacement therapies show promise, but face two major hurdles: the transplanted cells often don't survive long enough to provide lasting benefits, and patients need to take powerful anti-rejection medications to prevent their immune system from attacking the cells.
Our enhanced MAP technology could help overcome these challenges in several important ways:
-Provides a protective environment that helps transplanted cells survive longer
-Promotes blood vessel growth to better nourish the transplanted cells
-Uses an injectable format that makes the procedure less invasive
-Works with existing anti-rejection medications
-Builds on technology already proven safe in human clinical trials
If successful, this research could lead to a treatment that restores natural insulin production in people with Type 1 diabetes. Instead of managing their disease through constant monitoring and injections, patients might receive a single injection of protected insulin-producing cells that could function for months or even years. This could dramatically improve quality of life for people with Type 1 diabetes while reducing their risk of long-term complications from the disease.
Most importantly, because we're improving an existing technology that's already in clinical trials rather than starting from scratch, our approach offers a clearer and potentially faster path to helping patients. This makes our research particularly relevant to addressing the immediate needs of the Type 1 diabetes community.